FebriDx FDA CLIA Waiver Unlocks US$313 Million US Market for Atomo’s Pascal Cassettes

Regulatory Breakthrough Opens US Market Floodgates

Atomo Diagnostics Limited (ASX:AT1) has found itself at the centre of a significant growth opportunity following the US Food and Drug Administration’s (FDA) CLIA waiver approval for Lumos Diagnostics’ FebriDx test. This regulatory clearance is a game changer, estimated to expand the addressable US market for FebriDx by approximately 15 times, unlocking a vast new revenue stream for both Lumos and Atomo.

The FebriDx test, designed to rapidly differentiate between viral and bacterial infections, has been commercialised exclusively within Atomo’s patented Pascal cassette. This device enhances usability and reliability, particularly for untrained users, a critical factor in securing the CLIA waiver. Atomo’s Pascal cassette is thus not just a component but a pivotal element underpinning FebriDx’s regulatory success.

Robust Supply Agreements Signal Long-Term Growth

Atomo’s role extends beyond technology licencing; it is the exclusive manufacturer and supplier of the Pascal cassettes used in FebriDx tests. The company has a binding supply agreement with Lumos that runs until June 2031, which includes minimum annual purchase commitments and shortfall penalties, ensuring a steady revenue stream. Since the July 2025 agreement between Lumos and PHASE Scientific, Atomo has already received orders worth approximately A$1.57 million, with contracted revenues projected to reach US$3.4 million (A$5.2 million) based on the newly secured CLIA waiver.

The Lumos-PHASE Scientific contract itself is substantial, with minimum order quantities potentially generating up to US$313 million in FebriDx revenues over six years. Given that each FebriDx test requires an assembled Pascal cassette from Atomo, the company is poised to benefit significantly from this large-scale supply chain demand.

Scaling Up to Meet Growing Demand

Atomo’s Managing Director, John Kelly, emphasised the company’s pride in Pascal’s role in achieving the CLIA waiver and highlighted ongoing efforts to scale up production. The company is not only fulfilling Lumos’s current orders but is also preparing to meet demand from other pipeline customers who have recognised Pascal’s performance and its critical role in securing regulatory approvals in the US market.

This scaling effort reflects Atomo’s strategic positioning within the global rapid diagnostic test market, where ease of use and reliability are paramount. The Pascal cassette’s success with FebriDx could pave the way for broader adoption across other diagnostic applications, potentially expanding Atomo’s market footprint beyond infectious diseases.

Looking Ahead

While the CLIA waiver approval is a significant milestone, the actual financial impact for Atomo will depend on Lumos’s ability to ramp up production and market penetration in the US. Nonetheless, the secured supply agreements and the scale of the Lumos-PHASE Scientific contract provide a strong foundation for sustained revenue growth over the coming years.